CoChat

Hypoxia inducible factor (HIF) as a model for studying inhibition of protein–protein interactions

Open access

The DOI matches its Crossref record; 135 of the 136 references it cites were found in a registry or an index.

Abstract

The state of the art in identifying protein–protein interaction inhibitors of hypoxia inducible factor – a promising target for anticancer drug design – is described.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1039/c7sc00388a

Cites

135 of 135 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 (a) Schematic depicting HIF pathway under normoxic and hypoxic conditions. HIF-1α – hypoxia inducible factor 1α, HIF-1β – hypoxia inducible factor 1β, PHD – prolyl hydroxylase domain, HRE – hypoxic response element (b) domain structure of HIF-1α. bHLH – basic helix-loop-helix, PAS – per ARNT-AHR-Sim, ODDD – oxygen-dependent degradation domain, NTAD – N-terminal transactivation domain, CTAD – C-terminal transactivation domain (c) domain structures of HIF-1β (d) domain structure of p300/CBP.
Fig. 1 (a) Schematic depicting HIF pathway under normoxic and hypoxic conditions. HIF-1α – hypoxia inducible factor 1α, HIF-1β – hypoxia inducible factor 1β, PHD – prolyl hydroxylase domain, HRE – hypoxic response element (b) domain structure of HIF-1α. bHLH – basic helix-loop-helix, PAS – per ARNT-AHR-Sim, ODDD – oxygen-dependent degradation domain, NTAD – N-terminal transactivation domain, CTAD – C-terminal transactivation domain (c) domain structures of HIF-1β (d) domain structure of p300/CBP.CC BY · PubMed Central
Fig. 2 (a) Structure of the heterodimeric HIF-1α: ARNT PAS-B complex excised from its ternary complex with DNA (one subunit cyan, one forest green) PDB ID: 4ZPR (b) (i) NMR structure of complex between HIF-1α CTAD (cyan) and p300 CH1 domain (forest green) PDB ID: ; 1L8C (ii) primary sequence of HIF-1α CTAD with helical regions indicated.
Fig. 2 (a) Structure of the heterodimeric HIF-1α: ARNT PAS-B complex excised from its ternary complex with DNA (one subunit cyan, one forest green) PDB ID: 4ZPR (b) (i) NMR structure of complex between HIF-1α CTAD (cyan) and p300 CH1 domain (forest green) PDB ID: ; 1L8C (ii) primary sequence of HIF-1α CTAD with helical regions indicated.CC BY · PubMed Central
Fig. 3 Modulators of the HIF pathway (a) topotecan and derivative EZN-2208 (b) 2-oxoglutarate (c) DMOG and oxalyl glycine (d) FG-2216 (e) roxadustat (f) geldanamycin (g) ganetespib (h) X-ray crystal structure of a hydroxyproline derived inhibitor (orange) bound to pVHL (cyan), PDB ID: 3zrc (i) optimised hydroxyproline derived pVHL inhibitor VH298 (j) echinomycin (k) DNA sequence specific polyamide (l) bortezomib.
Fig. 3 Modulators of the HIF pathway (a) topotecan and derivative EZN-2208 (b) 2-oxoglutarate (c) DMOG and oxalyl glycine (d) FG-2216 (e) roxadustat (f) geldanamycin (g) ganetespib (h) X-ray crystal structure of a hydroxyproline derived inhibitor (orange) bound to pVHL (cyan), PDB ID: 3zrc (i) optimised hydroxyproline derived pVHL inhibitor VH298 (j) echinomycin (k) DNA sequence specific polyamide (l) bortezomib.CC BY · PubMed Central
Fig. 4 Reported small molecule HIF-1α/p300 inhibitors.
Fig. 4 Reported small molecule HIF-1α/p300 inhibitors.CC BY · PubMed Central
Fig. 5 Small molecule modulators of ARNT/TACC3 interaction.
Fig. 5 Small molecule modulators of ARNT/TACC3 interaction.CC BY · PubMed Central
Fig. 6 HIF-2 heterodimerization inhibitors (a) structure of a HIF-2α-PAS B ligand able to inhibit dimerization with ARNT PAS B through an allosteric mechanism (b) structure (PDB ID 4GHI) of compound shown in (a) (orange) bound to HIF-2α-PAS B (green), the arrow points to the β-sheet distal to the site of small molecule binding where HSQC shifts were observed and used to rationalise inhibition of heterdimerization with ARNT (c) compounds used to validate HIF-2 as a target in renal cancers.
Fig. 6 HIF-2 heterodimerization inhibitors (a) structure of a HIF-2α-PAS B ligand able to inhibit dimerization with ARNT PAS B through an allosteric mechanism (b) structure (PDB ID 4GHI) of compound shown in (a) (orange) bound to HIF-2α-PAS B (green), the arrow points to the β-sheet distal to the site of small molecule binding where HSQC shifts were observed and used to rationalise inhibition of heterdimerization with ARNT (c) compounds used to validate HIF-2 as a target in renal cancers.CC BY · PubMed Central
Fig. 7 Structures of peptide and protein derived modulators of HIF PPIs identified using selection methods (a) cyclic peptide inhibitor of HIF-1α/HIF-1β dimerization identified using SICLOPPS (b) FITC functionalized p300 binding peptides identified by phage display (c) X-ray structure of p300 binding Affimer (cyan with binding loops in orange) PDB ID: 5A0O.
Fig. 7 Structures of peptide and protein derived modulators of HIF PPIs identified using selection methods (a) cyclic peptide inhibitor of HIF-1α/HIF-1β dimerization identified using SICLOPPS (b) FITC functionalized p300 binding peptides identified by phage display (c) X-ray structure of p300 binding Affimer (cyan with binding loops in orange) PDB ID: 5A0O.CC BY · PubMed Central
Fig. 8 Hydrogen-bond surrogate constrained peptides that mimic helix 2 and 3 of HIF-1α as inhibitors of the HIF-1α/p300 interaction.
Fig. 8 Hydrogen-bond surrogate constrained peptides that mimic helix 2 and 3 of HIF-1α as inhibitors of the HIF-1α/p300 interaction.CC BY · PubMed Central
Fig. 9 Helix mimetics as inhibitors of the HIF-1α/p300 interaction (a) aromatic oligoamide helix mimetics of helix 1 and 2 (b) “bionic” protein approach for HIF-1α/p300 interaction whereby a segment of HIF-1α is replaced with an aromatic oligoamide helix mimetic leading to comparable affinity to the peptide sequence and superior selectivity to the aromatic oligoamide helix mimetic for the hybrid (c) oxopiperazine helix mimetics of HIF-1α helix 3.
Fig. 9 Helix mimetics as inhibitors of the HIF-1α/p300 interaction (a) aromatic oligoamide helix mimetics of helix 1 and 2 (b) “bionic” protein approach for HIF-1α/p300 interaction whereby a segment of HIF-1α is replaced with an aromatic oligoamide helix mimetic leading to comparable affinity to the peptide sequence and superior selectivity to the aromatic oligoamide helix mimetic for the hybrid (c) oxopiperazine helix mimetics of HIF-1α helix 3.CC BY · PubMed Central
George M. Burslem
George M. BurslemCC BY · PubMed Central
Hannah F. Kyle
Hannah F. KyleCC BY · PubMed Central
Adam Nelson
Adam NelsonCC BY · PubMed Central
Thomas A. Edwards
Thomas A. EdwardsCC BY · PubMed Central
Andrew J. Wilson
Andrew J. WilsonCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

2 retracted

Show all 135 references

Research works printed but not linked: 2

  1. Zhong, 1999, Cancer Res., 59, 5830
  2. Burslem, 2014, Synlett, 25, 324

Cited by

Metadata

Authors
Burslem, G. M., Kyle, H. F., Nelson, A., Edwards, T. A., & Wilson, A. J.
Affiliations
University of Leeds (GB)
Corresponding author
Wilson, Andrew J.
Venue
Chemical Science
Published
2017
Volume
8
Issue
6
Pages
4188-4202
ISSN
  • 2041-6520 (ISSN-L)
  • 2041-6539
OpenAlex
W2608188974
Cited by
39
References
136
Citations by year
2025: 4 · 2024: 4 · 2023: 6 · 2022: 6 · 2021: 3 · 2020: 6 · 2019: 3 · 2018: 5 · 2017: 1
FWCI
1.37
Type
journal article
Language
en
Open access
Locations
  • Chemical Science (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
  • University of Birmingham Research Portal (University of Birmingham) (submittedVersion, other-oa)
Funders
  • European Research Council (ERC-StG-240324, ERC-PoC 632207)
  • EPSRC (EP/N025652/1)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
  • Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
Keywords
hypoxia-inducible factor, protein-protein interaction, HIF inhibition, cancer chemotherapy, tumor hypoxia, tumor angiogenesis, HIF-1α, HIF-2α, oncology drug targets

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.